Galapagos and Cystic Fibrosis Foundation Therapeutics Extend Target Discovery Alliance
15-month extension exceeds Euro$800,000 in research fees.!--h2>
The target discovery alliance between Galapagos’ service division BioFocus, and Cystic Fibrosis Foundation Therapeutics, the drug discovery and development affiliate of the Cystic Fibrosis Foundation, has been extended. This 15-month extension exceeds Euro$800,000 in research fees and builds further on the alliance initiated in April 2005. BioFocus is applying its SilenceSelect adenoviral library and expertise in assay design to discover novel drug targets for the development of new cystic fibrosis therapies.